Facebook
X
LinkedIn
ForwardContemporary Considerations in Managing Thyroid Malignancy
The management of thyroid cancer is constantly evolving with new guidelines and new therapies available to support patients. Failure to stay informed leads to lower quality of care by practicing clinicians.
It is imperative that the surgeons, medical oncologists and endocrinologists remain current in the state-of-the-art techniques. This session provides attendees the opportunity to gain exposure to the latest science in thyroid cancer. Attendees need to determine when and how the latest science will affect their day-to-day practice and thus be able to narrow competency gaps across the work up and the various treatment options for thyroid cancer.
A panel discussion with experts from head and neck surgery, medical oncology and endocrinology discuss several relevant topics such as anaplastic cancer, papillary cancer and medullary cancer. We discuss contemporary workup and treatment options.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand the work up for thyroid nodules and indications for genetic testing.
- Be aware of the issues associated with GLP-1 drugs and risk for medullary cancer.
- Triage a patient with anaplastic thyroid cancer into the correct treatment pathway.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.75 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.